AstraZeneca Scraps Volrustomig Lung Trial as Enhertu Data Offsets Pipeline Setback

The simultaneous release of a pipeline discontinuation and a positive late-stage readout produced an unusually clean natural experiment in how the market prices AstraZeneca's oncology franchise. Volrustomig, a PD-1/CTLA-4 bispecific positioned as a cornerstone of the company's post-Imfinzi immuno-oncology strategy, has been pulled from its late-stage lung programme after data failed to clear the internal bar — removing a long-dated optionality item from consensus models and raising questions about the broader bispecific checkpoint thesis that several large-cap peers have also underwritten. Offsetting this, Enhertu demonstrated a progression-free survival benefit in lung cancer, extending the antibody-drug conjugate's label runway beyond breast and gastric indications into a substantially larger addressable population. That the shares rose on net is instructive: investors are currently rewarding near-term revenue visibility from de-risked ADC assets over speculative discovery-stage upside. The read-across favours the ADC complex and is a modest negative for pure-play checkpoint developers.